CO2 Energy Transition Corp. - Right Bolsa (NASDAQ: NOEMR)

Últimas noticias sobre CO2 Energy Transition Corp. - Right (NASDAQ:NOEMR) Bolsa

CO2 Energy Transition Corp. - Right

WIIM

COLD

Americold Realty Trust shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 FFO guidance.

Goldman Sachs analyst Eric Sheridan maintains Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) with a Buy and raises the price target from $41 to $47.

News

Price Target

Analyst Ratings

FVRR

Goldman Sachs Maintains Buy on Fiverr Intl, Raises Price Target to $47

BROS

Dutch Bros shares are trading higher after Baird raised its price target on the stock from $66 to $72.

DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) (the "Company") announced today the purchase of 20,473 Solana ("SOL") valued at approximately $2.97 million. This marks the Company's ninth Solana purchase under its digital asset treasury strategy. Following the transaction, DeFi Development Corp. now holds a total of 420,690 SOL, valued at approximately $61.9 million, inclusive of staking rewards.
Below is a summary of DeFi Dev Corp's current SOL position and key per-share metrics as of May 08, 2025:
<ul>
<li>Total SOL Held: 420,690</li>
<li>Total SOL Held (USD): approximately $61.9 million</li>
<li>Total Shares Outstanding: 2,011,887</li>
<li>SOL per Share ("SPS"): 0.209</li>
<li>SPS (USD): $30.78</li>
</ul>
As with all previously purchased tokens, the most recently purchased SOL will be held long-term and staked to a variety of validators, including DeFi Dev Corp.'s own Solana validators to generate native yield.

DFDV

DeFi Development Purchases 20,473 Solana Valued At About $2.97M

Goldman Sachs analyst Eric Sheridan maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Neutral and raises the price target from $135 to $155.

Goldman Sachs Maintains Neutral on Electronic Arts, Raises Price Target to $155

MTCH

Match Group shares are trading lower after the company reported a Q1 EPS miss and announced a 13% reduction in its workforce.

EPAM Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) reported <a href="https://www.benzinga.com/pressreleases/25/05/n45279186/epam-reports-results-for-first-quarter-2025-and-raises-full-year-revenue-outlook" target="_blank" rel="noreferrer noopener">first-quarter</a> 2025 results on Thursday. Its sales grew 11.7% year-over-year to $1.302 billion, beating the analyst consensus estimate of $1.28 billion.
On an organic constant currency basis, revenue increased by 1.4% YoY.
Adjusted EPS of $2.41 is down from $2.56 a year ago, but beat the consensus <a href="https://www.benzinga.com/earnings">estimate of $2.27</a>.
Adjusted operating income for the quarter reached $175.8 million, up 1.2% YoY, and the margin stood at 13.5%, down from 14.9% YoY.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45285797/forget-rate-cuts-this-year-bank-of-america-warns-after-powells-hawkish-tone">Forget Rate Cuts This Year, Bank Of America Warns After Powell&#8217;s Hawkish Tone</a>
The company's operating cash flow for the first quarter dropped to $24.2 million from $129.9 million year over year. Total cash fell 8.7% to $1.179 billion from $1.290 billion at year-end 2024.
EPAM repurchased 796,000 shares for $160 million in Q1 2025, with $277 million still authorized.
Total headcount reached ~61,700, including ~55,600 delivery professionals, up 0.9% since December 2024.
Second-quarter Outlook: EAPM expects revenue of $1.325 billion to $1.340 billion versus an estimated $1.30 billion, and adjusted EPS of $2.56 to $2.64 versus the $2.47 consensus.
2025 Outlook Raised: Revenue growth raised to 11.5% to 14.5% (or 2.0% to 5.0% organic, constant currency). The company now expects Sales Guidance of $5.27 billion to $5.41 billion (prior from $5.20 billion to $5.39 billion) versus the $5.27 billion consensus.
The company expects Adjusted EPS of $10.70 to $10.95 (prior $10.45 to $10.75) versus the consensus of $10.50. It sees GAAP operating margin at 9.0% to 10% and non-GAAP at 14.5% to 15.5%.
EPAM narrowed its GAAP EPS guidance from $6.78 to 7.08 to $6.78 to $7.00, compared to the $6.88 consensus.
Additionally, EPAM <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45279231/epam-announces-planned-leadership-succession" rel="noreferrer noopener">announced</a> that founder and CEO Arkadiy Dobkin will become Executive Chairman on September 1, 2025, with Balazs Fejes appointed as the new President and CEO to lead the company's next growth phase.
Price Action: EPAM shares are trading higher by 13.7% to $180.98 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45288753/google-at-staggering-42-discount-to-sp-500-after-150-billion-value-dive">Google At Staggering 42% Discount To S&amp;P 500 After $150 Billion Value Dive</a></li>
</ul>
Photo by Jobs 51 via Shutterstock

Earnings

Guidance

Movers

Tech

EPAM

EPAM Soars On Strong Q1 Earnings, Raised Guidance

DHI Group shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and issued FY25 sales guidance with its midpoint above estimates.

Koppers Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOP#NYSE">KOP</a>) is preparing to release its quarterly earnings on Friday, 2025-05-09. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Koppers Hldgs to report an earnings per share (EPS) of $0.56.
The market awaits Koppers Hldgs's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.14 in the last quarter, leading to a 0.48% drop in the share price on the following day.
Here's a look at Koppers Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.91</td>
<td>1.30</td>
<td>1.27</td>
<td>0.67</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.77</td>
<td>1.37</td>
<td>1.36</td>
<td>0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716541_0.png" alt="eps graph" />
<h3>Tracking Koppers Hldgs's Stock Performance</h3>
Shares of Koppers Hldgs were trading at $25.04 as of May 07. Over the last 52-week period, shares are down 41.83%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Koppers Hldgs</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Koppers Hldgs.
Koppers Hldgs has received a total of 2 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $64.0, the consensus suggests a potential 155.59% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of AdvanSix, Orion and Mativ Holdings, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for AdvanSix, with an average 1-year price target of $30.5, suggesting a potential 21.81% upside.</li>
<li>Analysts currently favor an Buy trajectory for Orion, with an average 1-year price target of $17.33, suggesting a potential 30.79% downside.</li>
<li>Analysts currently favor an Buy trajectory for Mativ Holdings, with an average 1-year price target of $10.0, suggesting a potential 60.06% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for AdvanSix, Orion and Mativ Holdings, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koppers Hldgs</td>
<td>Outperform</td>
<td>-7.05%</td>
<td>$83.60M</td>
<td>-2.00%</td>
</tr>
<tr>
<td>AdvanSix</td>
<td>Neutral</td>
<td>12.16%</td>
<td>$53.47M</td>
<td>2.98%</td>
</tr>
<tr>
<td>Orion</td>
<td>Buy</td>
<td>-7.26%</td>
<td>$89.30M</td>
<td>3.62%</td>
</tr>
<tr>
<td>Mativ Holdings</td>
<td>Buy</td>
<td>1.39%</td>
<td>$77.60M</td>
<td>0.17%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Koppers Hldgs ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages indicating a decline. However, it ranks in the middle for Return on Equity. Overall, Koppers Hldgs is positioned lower compared to its peers in terms of financial performance metrics.
<h3>Delving into Koppers Hldgs's Background</h3>
Koppers Holdings Inc through its subsidiaries, manufactures and sells wood products, wood treatment chemicals, and carbon compounds used in markets such as railroad, aluminum and steel, agriculture, utilities, and residential lumber. The company is organized into three business segments: railroad and utility products and services, performance chemicals, and carbon materials and chemicals. Its product portfolio includes treated and untreated wood products like crossties used in railroads, wood preservation chemicals, and carbon compounds such as creosote used in the treatment of wood crossties, among others. The majority of its revenue comes from the company's railroad and utility products and services segment, and more than half of the company's revenue is earned in the United States.
<h3>Koppers Hldgs's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Koppers Hldgs faced challenges, resulting in a decline of approximately -7.05% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Koppers Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.14% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Koppers Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.0%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.53%, the company showcases effective utilization of assets.
Debt Management: Koppers Hldgs's debt-to-equity ratio surpasses industry norms, standing at 2.09. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/KOP/earnings">To track all earnings releases for Koppers Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Koppers Hldgs

Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Kymera Therapeutics to report an earnings per share (EPS) of $-0.90.
The announcement from Kymera Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.09, leading to a 3.64% increase in the share price on the subsequent day.
Here's a look at Kymera Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.79</td>
<td>-0.84</td>
<td>-0.68</td>
<td>-0.73</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.88</td>
<td>-0.82</td>
<td>-0.58</td>
<td>-0.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>1.0%</td>
<td>4.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716529_0.png" alt="eps graph" />
<h3>Kymera Therapeutics Share Price Analysis</h3>
Shares of Kymera Therapeutics were trading at $29.11 as of May 07. Over the last 52-week period, shares are down 21.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Kymera Therapeutics</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Kymera Therapeutics.
A total of 2 analyst ratings have been received for Kymera Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $56.0, suggesting a potential 92.37% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Kiniksa Pharmaceuticals, Twist Bioscience and Travere Therapeutics, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Kiniksa Pharmaceuticals, with an average 1-year price target of $39.67, suggesting a potential 36.28% upside.</li>
<li>Analysts currently favor an Buy trajectory for Twist Bioscience, with an average 1-year price target of $44.0, suggesting a potential 51.15% upside.</li>
<li>Analysts currently favor an Buy trajectory for Travere Therapeutics, with an average 1-year price target of $37.9, suggesting a potential 30.2% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
The peer analysis summary outlines pivotal metrics for Kiniksa Pharmaceuticals, Twist Bioscience and Travere Therapeutics, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amicus Therapeutics</td>
<td>Buy</td>
<td>13.45%</td>
<td>$113.55M</td>
<td>-11.19%</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals</td>
<td>Buy</td>
<td>72.54%</td>
<td>$76.13M</td>
<td>1.91%</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>Buy</td>
<td>23.23%</td>
<td>$46.03M</td>
<td>-8.78%</td>
</tr>
<tr>
<td>Travere Therapeutics</td>
<td>Buy</td>
<td>97.54%</td>
<td>$77.05M</td>
<td>-89.72%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Kymera Therapeutics ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>Discovering Kymera Therapeutics: A Closer Look</h3>
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
<h3>Kymera Therapeutics: A Financial Overview</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Negative Revenue Trend: Examining Kymera Therapeutics's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -84.56% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Kymera Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -956.88%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kymera Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.19% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.03%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Kymera Therapeutics's debt-to-equity ratio is below the industry average at 0.11, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/KYMR/earnings">To track all earnings releases for Kymera Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KYMR

What's Next: Kymera Therapeutics's Earnings Preview

Embecta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) is gearing up to announce its quarterly earnings on Friday, 2025-05-09. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Embecta will report an earnings per share (EPS) of $0.67.
Investors in Embecta are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.21, which was followed by a 1.75% drop in the share price the next day.
Here's a look at Embecta's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.36</td>
<td>0.46</td>
<td>0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.65</td>
<td>0.45</td>
<td>0.74</td>
<td>0.67</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>10.0%</td>
<td>7.000000000000001%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716520_0.png" alt="eps graph" />
<h3>Market Performance of Embecta's Stock</h3>
Shares of Embecta were trading at $12.47 as of May 07. Over the last 52-week period, shares are down 9.69%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/EMBC/earnings">To track all earnings releases for Embecta visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EMBC

A Peek at Embecta's Future Earnings

Alpha Metallurgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMR#NYSE">AMR</a>) will release its quarterly earnings report on Friday, 2025-05-09. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Alpha Metallurgical to report an earnings per share (EPS) of $-0.17.
The announcement from Alpha Metallurgical is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Alpha Metallurgical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.16</td>
<td>1.03</td>
<td>4.34</td>
<td>10.82</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>0.29</td>
<td>4.49</td>
<td>9.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-3.0%</td>
<td>0.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716512_0.png" alt="eps graph" />
<h3>Tracking Alpha Metallurgical's Stock Performance</h3>
Shares of Alpha Metallurgical were trading at $125.83 as of May 07. Over the last 52-week period, shares are down 56.75%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Opinions on Alpha Metallurgical</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Alpha Metallurgical.
A total of 1 analyst ratings have been received for Alpha Metallurgical, with the consensus rating being Buy. The average one-year price target stands at $183.0, suggesting a potential 45.43% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Worthington Steel, Warrior Met Coal and Ryerson Holding, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Worthington Steel, with an average 1-year price target of $34.0, suggesting a potential 72.98% downside.</li>
<li>Analysts currently favor an Buy trajectory for Warrior Met Coal, with an average 1-year price target of $70.67, suggesting a potential 43.84% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Ryerson Holding, with an average 1-year price target of $25.0, suggesting a potential 80.13% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Worthington Steel, Warrior Met Coal and Ryerson Holding, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha Metallurgical</td>
<td>Buy</td>
<td>-35.69%</td>
<td>$34.08M</td>
<td>-0.13%</td>
</tr>
<tr>
<td>Worthington Steel</td>
<td>Outperform</td>
<td>-14.69%</td>
<td>$81.20M</td>
<td>1.36%</td>
</tr>
<tr>
<td>Warrior Met Coal</td>
<td>Buy</td>
<td>-40.43%</td>
<td>$1.06M</td>
<td>-0.39%</td>
</tr>
<tr>
<td>Ryerson Holding</td>
<td>Neutral</td>
<td>-8.35%</td>
<td>$204.40M</td>
<td>-0.69%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Alpha Metallurgical ranks at the bottom for Revenue Growth among its peers. It also has the lowest Gross Profit and Return on Equity compared to the others.
<h3>About Alpha Metallurgical</h3>
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
<h3>Alpha Metallurgical's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Alpha Metallurgical's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -35.69% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Alpha Metallurgical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -0.34%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Alpha Metallurgical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.13%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Alpha Metallurgical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.09%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Alpha Metallurgical's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/AMR/earnings">To track all earnings releases for Alpha Metallurgical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Alpha Metallurgical's Earnings Expectations

Disclosed on May 7, Randall K Fields, Chief Executive Officer at ReposiTrak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRAK#NYSE">TRAK</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0000050471/000141588925012234//Archives/edgar/data/50471/000141588925012234/0001415889-25-012234-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Fields sold 7,500 shares of ReposiTrak. The total transaction amounted to $161,904. 
Monitoring the market, ReposiTrak's shares up by 2.18% at $22.0 during Thursday's morning.
<h3>Discovering ReposiTrak: A Closer Look</h3>
ReposiTrak Inc is a software as a service provider with extensive capabilities that gives their customers an easy, cost-efficient way to expand their services to their benefit. The company and its subsidiaries develop, market, and support proprietary software products. These products assist the management of business operations, which helps clients to make more informed decisions. The company also provides a cloud-based solution to remain in compliance with business records and regulatory requirements. The firm's services comprise implementation, business optimization, outsourcing, technical services, education, and application hosting.
<h3>A Deep Dive into ReposiTrak's Financials</h3>
Revenue Growth: ReposiTrak's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 7.12%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 81.74%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): ReposiTrak's EPS is below the industry average. The company faced challenges with a current EPS of 0.08. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: ReposiTrak's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current Price to Earnings ratio of 67.28 is higher than the industry average, indicating the stock is priced at a premium level according to the market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 19.38 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an impressive EV/EBITDA ratio of 45.38, ReposiTrak demonstrates exemplary market valuation, surpassing industry averages.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000050471">Check Out The Full List Of ReposiTrak's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

TRAK

Chief Executive Officer Of ReposiTrak Sold $161K In Stock

Richard P Rowe, Director at FutureFuel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>), reported an insider buy on May 7, according to a new SEC filing. 
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001337298/000143774925015142//Archives/edgar/data/1337298/000143774925015142/0001437749-25-015142-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Rowe increased their investment in FutureFuel by purchasing 15,000 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $59,250.
During Thursday's morning session, FutureFuel shares down by 0.0%, currently priced at $3.99.
<h3>Discovering FutureFuel: A Closer Look</h3>
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.
<h3>Financial Insights: FutureFuel</h3>
Decline in Revenue: Over the 3 months period, FutureFuel faced challenges, resulting in a decline of approximately -33.15% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 9.1%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): FutureFuel's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 0.06.
</li>
</ul>
Debt Management: FutureFuel's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 11.4, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 0.72 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 1.62 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Delving Into the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001337298">Check Out The Full List Of FutureFuel's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Director Of FutureFuel Makes $59K Buy

An official report on May 7, 2025 reveals Senator Shelley M Capito's recent sale of Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) stock, valued between $2,002 and $30,000. The transaction took place on May 7, 2025, as per the May filing.
At this time, Target shares are trading up 1.2% at $96.64.
<h3>Senator's Recent Trading Activity</h3>
In the past three years, Shelley M Capito made 122 stock trades totaling more than $206 thousand. The largest trades involved stocks like Intel and Duke Energy. Their most notable trades made recently include key transactions: 
<ul>
<li>Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): $1,001 - $15,000 Purchase</li>
<li>Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>): $1,001 - $15,000 Sale</li>
<li>Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>): $1,001 - $15,000 Sale</li>
</ul>
Here's a summary of Shelley M Capito's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alphabet</td>
<td>GOOGL</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-04-29</td>
</tr>
<tr>
<td>Target</td>
<td>TGT</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-11</td>
</tr>
<tr>
<td>Nike</td>
<td>NKE</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>S</td>
<td>2025-04-10</td>
</tr>
<tr>
<td>Meta Platforms</td>
<td>META</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-26</td>
</tr>
<tr>
<td>Constellation Energy</td>
<td>CEG</td>
<td>STOCK</td>
<td>$1,001 - $15,000</td>
<td>P</td>
<td>2025-03-26</td>
</tr>
</tbody>
</table>
Stay informed on Shelley M Capito's trades and other members of Congress with our real-time <a href="https://www.benzinga.com/gov-trades/members/shelley-m-capito">government trades tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

General

GOOGL

A Congress Member Sold Up To $30K In Target Stock: Here's What You Need To Know

NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that NeoGenomics will report an earnings per share (EPS) of $-0.01. 
The market awaits NeoGenomics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 2.54% increase in the share price on the subsequent day.
Here's a look at NeoGenomics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.01</td>
<td>0.03</td>
<td>0.01</td>
<td>0</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0</td>
<td>0.04</td>
<td>0.05</td>
<td>0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>4.0%</td>
<td>18.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746716500_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of NeoGenomics were trading at $8.0 as of May 07. Over the last 52-week period, shares are down 49.08%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Insights Shared by Analysts on NeoGenomics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding NeoGenomics.
The consensus rating for NeoGenomics is Buy, based on 9 analyst ratings. With an average one-year price target of $12.94, there's a potential 61.75% upside.
<h3>Comparing Ratings with Competitors</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of OPKO Health, Pennant Gr and Pediatrix Medical Group, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for OPKO Health, with an average 1-year price target of $2.68, suggesting a potential 66.5% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Pennant Gr, with an average 1-year price target of $34.67, suggesting a potential 333.38% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Pediatrix Medical Group, with an average 1-year price target of $18.12, suggesting a potential 126.5% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
In the peer analysis summary, key metrics for OPKO Health, Pennant Gr and Pediatrix Medical Group are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NeoGenomics</td>
<td>Buy</td>
<td>7.55%</td>
<td>$73.25M</td>
<td>-2.90%</td>
</tr>
<tr>
<td>OPKO Health</td>
<td>Buy</td>
<td>-13.66%</td>
<td>$42.62M</td>
<td>-5.05%</td>
</tr>
<tr>
<td>Pennant Gr</td>
<td>Outperform</td>
<td>29.42%</td>
<td>$25.00M</td>
<td>2.49%</td>
</tr>
<tr>
<td>Pediatrix Medical Group</td>
<td>Neutral</td>
<td>-7.42%</td>
<td>$102.64M</td>
<td>2.67%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NeoGenomics ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>All You Need to Know About NeoGenomics</h3>
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
<h3>Understanding the Numbers: NeoGenomics's Finances</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, NeoGenomics showcased positive performance, achieving a revenue growth rate of 7.55% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: NeoGenomics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -15.43%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NeoGenomics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.9%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): NeoGenomics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -1.6%, the company may face hurdles in achieving optimal financial performance.
Debt Management: NeoGenomics's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/NEO/earnings">To track all earnings releases for NeoGenomics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at NeoGenomics's Upcoming Earnings Report

Lee Bradley Soultz, Chief Executive Officer at WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>), reported an insider buy on May 7, according to a new SEC filing. 
What Happened: In a significant move reported in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001647088/000089706925000945//Archives/edgar/data/1647088/000089706925000945/0000897069-25-000945-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday, Soultz purchased 10,000 shares of WillScot Holdings, demonstrating confidence in the company's growth potential. The total value of the transaction stands at $267,900.
During Thursday's morning session, WillScot Holdings shares up by 1.55%, currently priced at $26.9.
<h3>All You Need to Know About WillScot Holdings</h3>
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
<h3>Financial Milestones: WillScot Holdings's Journey</h3>
Negative Revenue Trend: Examining WillScot Holdings's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -4.71% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 53.68%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): WillScot Holdings's EPS reflects a decline, falling below the industry average with a current EPS of 0.23.
</li>
</ul>
Debt Management: WillScot Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.84, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Evaluating Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: WillScot Holdings's stock is currently priced at a premium level, as reflected in the higher-than-average P/E ratio of 331.12.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 2.11 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 13.54 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001647088">Check Out The Full List Of WillScot Holdings's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Lee Bradley Soultz Boosts Confidence With $267K Purchase Of WillScot Holdings Stock

First Majestic Silver shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results.

Goldman Sachs analyst Salveen Richter maintains CRISPR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) with a Neutral and lowers the price target from $53 to $47.

CRSP

Goldman Sachs Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $47

A notable insider purchase on May 8, was reported by Joseph Wm Foran, Chairman and CEO at Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>), based on the most recent SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001520006/000152000625000149//Archives/edgar/data/1520006/000152000625000149/0001520006-25-000149-index.htm">U.S. Securities and Exchange Commission</a> on Thursday unveiled that Foran made a notable purchase of 2,500 shares of Matador Resources, valuing at $99,075.
Matador Resources's shares are actively trading at $40.99, experiencing a up of 2.37% during Thursday's morning session.
<h3>Unveiling the Story Behind Matador Resources</h3>
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.
<h3>A Deep Dive into Matador Resources's Financials</h3>
Revenue Growth: Matador Resources's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 28.12%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 41.43%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Matador Resources's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.92.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 0.62, Matador Resources adopts a prudent financial strategy, indicating a balanced approach to debt management.
Exploring Valuation Metrics Landscape:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 5.37, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 1.36 is lower than the industry average, implying a discounted valuation for Matador Resources's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 3.24, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001520006">Check Out The Full List Of Matador Resources's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

CO2 Energy Transition Corp. - Right

Noticias

Últimas noticias sobre CO2 Energy Transition Corp. - Right (NASDAQ:NOEMR) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL